Annotation Detail
Information
- Associated Genes
- FGFR3
- Associated Variants
- FGFR3 FGFR3-TACC3
- Associated Disease
- cancer
- Source Database
- CIViC Evidence
- Description
- Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 5 partial responses (PR) and 16 with stable disease were seen. In patients harboring FGFR3-TACC3, there were 2 urothelial cancer patients with PRs, 1 endometrial cancer patient with PR (also had FGFR2-BICC1/FGFR2-OFD1 fusions), and tumor shrinkage in a patient with adrenal carcinoma (also had FGFR2-CCDC6 fusion).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1919
- Gene URL
- https://civic.genome.wustl.edu/links/genes/23
- Variant URL
- https://civic.genome.wustl.edu/links/variants/830
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Cancer
- Evidence Direction
- Supports
- Drug
- Erdafitinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26324363
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Erdafitinib | Sensitivity | true |